Prime Medicine, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Prime Medicine, Inc. (PRME) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 7.17 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.80M shares, a 44.10% decline year-over-year.
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 5.37M shares, a 24.64% increase year-over-year.
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 35.50K shares, a 78.68% decline year-over-year.
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 3.22M shares, a 771.80% increase year-over-year.
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.80M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 7.17M shares 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 5.37M shares 10-Q · filed 2026-05-07 | |||
| 2025-09-30 | 35.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 3.26M shares derived: sum of 2 quarters · filed 2025-11-07 | 7.57M shares 10-Q · filed 2025-11-07 | |
| 2025-06-30 | 3.22M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 7.53M shares 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | 4.31M shares 10-Q · filed 2025-05-08 | |||
| 2024-09-30 | 166.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 536.30K shares derived: sum of 2 quarters · filed 2024-11-12 | 4.43M shares 10-Q · filed 2024-11-12 | |
| 2024-06-30 | 369.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 4.27M shares 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 3.90M shares 10-Q · filed 2024-05-10 | |||
| 2023-09-30 | 446.48K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 1.05M shares derived: sum of 2 quarters · filed 2023-11-03 | 3.95M shares 10-Q · filed 2023-11-03 | |
| 2023-06-30 | 599.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 3.50M shares 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | 2.90M shares 10-Q · filed 2023-05-11 | |||
| 2022-09-30 | 1.16M shares 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | 0.00 shares 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |